Eli Lilly’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.
Related Posts
U.S. Lags Behind Other Countries in Hepatitis-C Cures
In the 10 years since the drugmaker Gilead debuted a revolutionary treatment for hepatitis C, a wave of new therapies…
Dry January: How to Set Yourself Up for Success
Dry January sounds like a simple proposition: No alcohol. For 31 days. And some enthusiasts jump in without much planning…
C.D.C. Shortens Isolation Period for People With Covid
Americans with Covid or other respiratory infections need not isolate for five days before returning to work or school, the…